What is Nalfon used for?

Nalfon is indicated for Osteoarthritis, Pain, Rheumatoid arthritis.

Nalfon is developed by Pharmaco.

What development phase is Nalfon in?

Nalfon is FDA-approved (marketed).

What are the side effects of Nalfon?

Common side effects include Dyspepsia, Nausea, Constipation, Headache, Somnolence, Dizziness.

What is the generic name of Nalfon?

FENOPROFEN is the generic (nonproprietary) name of Nalfon.

Last reviewed 2026-04-20 · How we verify

Nalfon (FENOPROFEN)

Pharmaco · FDA-approved approved Small molecule Quality 55/100

At a glance

Generic name	FENOPROFEN
Sponsor	Pharmaco
Drug class	Nonsteroidal Anti-inflammatory Drug
Target	Prostaglandin G/H synthase 1
Modality	Small molecule
Therapeutic area	Immunology
Phase	FDA-approved
First approval	1976

Approved indications

Osteoarthritis
Pain
Rheumatoid arthritis

Boxed warnings

Cardiovascular Thrombotic Events • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (see WARNINGS and PRECAUTIONS ). • Fenoprofen calcium tablets are contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see CONTRAINDICATIONS and WARNINGS ). Gastrointestinal Risk • NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration and perforation of stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS ).

Common side effects

Dyspepsia
Nausea
Constipation
Headache
Somnolence
Dizziness
Increased sweating
Pruritus
Tinnitus
Blurred vision
Vomiting
Abdominal pain

Drug interactions

lithium
methotrexate
phenprocoumon
warfarin

Key clinical trials

Comparison Between Two Different Doses of Nulbuphine _bupivacaine in TAP Block in Cancer Abdominal Surgeries (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Nalfon CI brief — competitive landscape report
Nalfon updates RSS · CI watch RSS
Pharmaco portfolio CI